Octaplas Pediatric Plasma Exchange Trial
Public ClinicalTrials.gov record NCT01938378. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Post-Marketing Requirement Study to Investigate the Safety and Tolerability of Octaplas™ in the Management of Pediatric Patients Who Require Therapeutic Plasma Exchange
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety and tolerability of octaplas™ in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters in pediatric patients who require therapeutic plasma exchange.
Study identification
- NCT ID
- NCT01938378
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 41 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 2 Years to 20 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2015 (Type not available)
- Primary completion
- Jan 27, 2019 (Actual)
- Completion
- Jan 27, 2019 (Actual)
- Last update posted
- Mar 24, 2020
2015 – 2019
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Octapharma Research Site | Birmingham | Alabama | 35233 | — |
| Octapharma Research Site | Atlanta | Georgia | 30322 | — |
| Octapharma Research Site | New Orleans | Louisiana | 70118 | — |
| Octapharma Research Site | Minneapolis | Minnesota | 55455 | — |
| Octapharma Research Site | Kansas City | Missouri | 64108 | — |
| Octapharma Research Site | St Louis | Missouri | 63130 | — |
| Octapharma Research Site | Durham | North Carolina | 27710 | — |
| Octapharma Research Site | Cincinnati | Ohio | 45229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01938378, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01938378 live on ClinicalTrials.gov.